Patents Assigned to U.S. Dept. Of Health and Human Services, (DHHS), U.S. Government
-
Patent number: 11872394Abstract: Described herein are systems and methods for the treatment of pain using electrical nerve conduction block (ENCB). Contrary to other methods of pain treatment, the ENCB can establish a direct block of neural activity, thereby eliminating the pain. Additionally, the ENCB can be administered without causing electrochemical damage. An example method can include: placing at least one electrode contact in electrical communication with a region of a subject's spinal cord; applying an electrical nerve conduction block (ENCB) to a nerve in the region through the at least one electrode contact; and blocking neural activity with the ENCB to reduce the pain or other unwanted sensation in the subject.Type: GrantFiled: May 13, 2021Date of Patent: January 16, 2024Assignees: CASE WESTERN RESERVE UNIVERAITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENTInventors: Niloy Bhadra, Narendra Bhadra, Kevin L Kilgore, Scott Lempka, Jesse Wainright, Tina Vrabec, Manfred Franke
-
Patent number: 11708612Abstract: Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment. Provided herein are methods of detecting gene expression in T cells and in monocytes as well as measuring relative abundance of particular immune cell populations and determining responsiveness to anticancer immunotherapy.Type: GrantFiled: December 2, 2020Date of Patent: July 25, 2023Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENTInventors: Andrea Bild, Jason I. Griffiths
-
Patent number: 11701361Abstract: Methods of using a phosphoinositide 3-kinase p110-delta inhibitor to treat, delay the onset, or slow the progression of an autoimmune disease or disorder in a subject, without suppressing the subject's B cell responses to exogenous antigens or rendering the subject immunocompromised, as well as pharmaceutical compositions containing phosphoinositide 3-kinase p110-delta inhibitors in amounts suitable for convenient and accurate administration within these therapeutic methods.Type: GrantFiled: January 7, 2019Date of Patent: July 18, 2023Assignees: NATIONAL INSTITUTES OF HEALTH (NCH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR), THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: John Cambier, Elizabeth Franks
-
Patent number: 11666569Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.Type: GrantFiled: May 14, 2020Date of Patent: June 6, 2023Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) U.S. GOVERNMENTInventors: Sergio A. Gradilone, Nicholas F. LaRusso
-
Patent number: 11612619Abstract: Compositions, methods, and systems for modifying sterol metabolism in a subject is disclosed. In some embodiments, the subjects may be administered one or more mammalian cells modified to express at least one sterol degrading enzyme derived from a bacterium. In many embodiments, the cell is a macrophage or monocyte stably expressing three or more enzymes that aid in opening the ? ring of cholesterol. The disclosed compositions and methods may be useful in lowering cholesterol levels in a subject in need thereof. In some embodiments, the subject may have a genetic predisposition to atherosclerosis.Type: GrantFiled: November 1, 2019Date of Patent: March 28, 2023Assignee: National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. GovernmentInventors: Richard Eric Honkanen, Brandon Marshall D'Arcy, Mark Raymond Swingle
-
Patent number: 11230722Abstract: Novel compounds and compositions containing (R)-3-hydroxybutyrate derivatives are disclosed. The compounds and compositions can be used as nutritional supplements to increase physical performance and as therapeutics to ameliorate symptoms of medical conditions, particularly neurological conditions, such as Alzheimer's and similar conditions. Novel methods for making R-3-hydroxybutyrate derivatives also are disclosed. Exemplary methods employ a supercritical solvent, such as supercritical carbon dioxide, and employ a lipase catalyzed esterification or transesterification reaction to produce the (R)-3-hydroxybutyrate derivatives.Type: GrantFiled: March 7, 2018Date of Patent: January 25, 2022Assignees: Oxford University Innovation Limited, U.S. Dept. Of Health and Human Services, (DHHS), U.S. GovernmentInventors: Richard Lewis Veech, Michael Todd King, Kieran Clarke
-
Patent number: 11090660Abstract: The present technology relates to improved device and methods of use of insulator-based dielectrophoresis. This device provides a multi-length scale element that provides enhanced resolution and separation. The device provides improved particle streamlines, trapping efficiency, and induces laterally similar environments. Also provided are methods of using the device.Type: GrantFiled: August 10, 2017Date of Patent: August 17, 2021Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENTInventors: Mark Hayes, Claire Crowther, Paul Jones
-
Patent number: 11040215Abstract: The present invention relates to compositions and methods configured to deliver a stimulus (e.g., a therapeutic agent or a therapeutically beneficial signal) to a cell, tissue, organ, or organism. The stimulus is applied at least twice, and the first and second applications are separated by a rest period in which no further stimulus is actively applied. The rest period is of a duration (e.g., about 1-6 hours) sufficient to provoke an enhanced response to the second stimulus.Type: GrantFiled: July 20, 2018Date of Patent: June 22, 2021Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS). U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)Inventors: Clinton Rubin, Janet Rubin
-
Patent number: 10660890Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.Type: GrantFiled: October 24, 2014Date of Patent: May 26, 2020Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)Inventors: Sergio A. Gradilone, Nicholas F. LaRusso
-
Patent number: 9588208Abstract: A method for accelerated segmented magnetic resonance (MR) image data acquisition includes using a plurality of RF pulses to excite one or more slices of an anatomical area of interest according to a predetermined slice acceleration factor. Next, a collapsed image comprising the slices is acquired using a consecutive segment acquisition process. Then, a parallel image reconstruction method is applied to the collapsed image to separate the collapsed image into a plurality of slice images.Type: GrantFiled: May 7, 2014Date of Patent: March 7, 2017Assignees: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government NIH Division of Extramural Inventions and Technology Resources (DEITR), Siemens Healthcare GmbHInventors: Jonathan Rizzo Polimeni, Himanshu Bhat, Keith Aaron Heberlein, Kawin Setsompop, Thomas Witzel, Stephen Farman Cauley
-
Patent number: 9439978Abstract: Provided herein are compositions comprising a micelle having a hydrophobic superparmagnetic iron oxide nanoparticle (SPION) core, a first coating comprising a cationic polymer, and a second coating comprising a polynucleotide. Also provided are methods of using the compositions for transfection and/or transformation of a cell with the polynucleotide. Further provided are methods of detecting transfection of a cell with the polynucleotide.Type: GrantFiled: September 28, 2012Date of Patent: September 13, 2016Assignees: University of South Florida, The United States of America as represented by National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. GovernmentInventors: Subhra Mohapatra, Chunyan Wang
-
Patent number: 9360539Abstract: A system for perfusion and diffusion MR imaging of a portion of patient anatomy includes an RF (Radio Frequency) signal generator for generating RF excitation pulses in anatomy and enabling subsequent acquisition of associated RF echo data. A magnetic field gradient generator generates anatomical volume select magnetic field gradients for phase encoding and readout RF data acquisition in a three dimensional (3D) anatomical volume. The RF signal generator and the gradient generator acquire within a single MR imaging scan, perfusion image data of the 3D volume, at least partially in the presence of contrast agent, and diffusion image data of the 3D volume.Type: GrantFiled: December 12, 2012Date of Patent: June 7, 2016Assignee: National Institute of Health (NIH), U.S. Dept. Of Health and Human Services (DHHS), U.S. GovernmentInventors: Timothy J Carroll, Yong Jeong, Sumeeth Vijay Jonathan, Parmede Vakil
-
Publication number: 20130156728Abstract: The present invention provides a composition effective for a neurological disease or an autoimmune disease and methods of making and using the same.Type: ApplicationFiled: May 26, 2011Publication date: June 20, 2013Applicant: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. GovernmentInventor: Daniel L. Kaufman
-
Publication number: 20120177567Abstract: The present invention provides methods for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients using an anti-CD22 immunotoxin. The methods disclosed comprise administering to a pediatric patient in need of that treatment an effective dose of a recombinant immunotoxin comprising a variable light (VL) chain linked to a variable heavy (VH) which is genetically fused to a therapeutic moiety comprising a Pseudomonas exotoxin A PE38 fragment. The recombinant immunotoxin specifically binds CD22 thereby inhibiting the growth of CD22-expressing (CD22+) ALL cancer cells.Type: ApplicationFiled: August 11, 2011Publication date: July 12, 2012Applicants: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MEDIMMUNE, LLCInventors: Alan S. WAYNE, Ira Pastan, Karen Kaucic, Robert Lechleider